Last reviewed · How we verify
Second-line systemic therapy
This drug targets the PD-1 receptor to inhibit cancer cell growth.
This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Second-line systemic therapy |
|---|---|
| Also known as | docetaxel-based chemotherapy, albumin-bound paclitaxel-based chemotherapy, immunotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially prolonged survival in patients with certain types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (PHASE3)
- A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
- The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer (PHASE2)
- EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis. (NA)
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer (PHASE2)
- Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Second-line systemic therapy CI brief — competitive landscape report
- Second-line systemic therapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI